ADM Tronics to Develop Patented, Next-Generation Ophthalmic Diagnostic System for RetinalGeniX Technologies, Inc.
January 13 2020 - 10:14AM
InvestorsHub NewsWire
ADM Tronics to Develop Patented,
Next-Generation Ophthalmic Diagnostic System for RetinalGeniX
Technologies, Inc.
Northvale, NJ -- January 13, 2020 -- InvestorsHub
NewsWire -- ADM Tronics Unlimited, Inc. (OTCQB:
ADMT) announced that RetinalGeniX Technologies, Inc.
(“RTI”), has entered into an engineering development agreement for
ADMT to develop and manufacture RTI’s patented, next-generation
ophthalmic diagnostic technology known as the RetinalGeniX™
system.
The RetinalGeniX system is a cost-effective, ultra-wide imaging
system to examine the periphery of the retina for the detection of
early signs of diabetic retinopathy (“DR”) without dilating a
patient’s pupils. RetinalGeniX was developed by
researchers at RTI and is covered by three patents.
ADMT will develop and engineer the RetinalGeniX system to meet
regulatory requirements and for quantity manufacturing in ADMT’s
FDA-Registered Medical Device Manufacturing Facility in Northvale,
NJ. Once the commercial-ready design of the RetinalGeniX
system is completed, ADMT will support RTI in regulatory submission
requirements for US FDA and international distribution to the
ophthalmic and ophthalmology markets.
Jerry Katzman, MD, Chairman, President and CEO of RTI, stated, “We
are pleased to be working with ADM Tronics to bring the
RetinalGeniX system to market readiness. There is a
significant need for a simpler and more affordable device for
uncomplicated but accurate imaging of a person’s retina to detect
symptoms of diabetic retinopathy. I know our RetinalGeniX
system fills that need and I am confident ADMT can help us to bring
this great technology to fruition.”
DR is a leading cause of vision loss globally. Of an
estimated 285 million people with diabetes mellitus, about
one-third, over 100 million, have signs of DR with approximately
one-third of those, or 35 million, threatened with blindness due to
diabetic maculopathy. Early detection of diabetes, by
observing vascular changes in the peripheral retina, not only
serves as an early warning for diabetes but also signals vascular
cerebral pathology and early signs of dementia. Early
diagnosis leads to more favorable outcomes in both diseases.
This technology will facilitate the mass screening of large
populations.
“We are excited that RTI has chosen our company for this important
project that can help so many people around the world,” stated
Andre’ DiMino, President and CEO of ADMT. “Our engineering
and regulatory teams look forward to working with Dr. Katzman and
researchers at RTI to bring the RetinalGeniX system to
commercialization.”
RTI is an emerging medical device company focused on
commercializing the next generation of cost-effective, ultra-wide
imaging technologies to examine the periphery of the retina, at up
to a 200° field of view, to detect early signs of diabetic
retinopathy. “We are dedicated to developing
technologies that advance the next generation of diagnostics.
Detected early and treated effectively, retinopathy can be stopped
so that vision can be maintained. The proliferation of tools
making early diagnosis easy and inexpensive is a critical factor in
broadening care,” stated Dr. Katzman. “Our relationship with
ADM Tronics for engineering the RetinalGeniX system helps us to
advance our efforts.”
About ADMT
ADMT is a diversified, technology-based developer and manufacturer
of innovative technologies and products. Its core competency
is its ability to conceptualize a technology, bring it through
development, into manufacturing and commercialization, all
in-house. ADMT has three areas of activity: Proprietary
Medical Devices; Medical Device Design, Engineering, Regulatory and
Manufacturing Services; and Eco-Friendly, Water-Based
Formulations. The Company’s headquarters, laboratories,
FDA-Registered medical device, and manufacturing operations are in
Northvale, NJ. ADMT’s multi-disciplinary team of engineers,
researchers, and technologists utilize advanced technology
infrastructure, such as rapid 3-D prototyping, precision
instrumentation and specialized software and peripherals, for
research, development, and commercialization of diversified
technologies. Additional information is available on the Company’s
website - admtronics.com.
Except for historical information contained herein, the matters set
forth in this news release are “forward-looking” statements (as
defined in the Private Securities Litigation Reform Act of 1995),
including statements regarding future revenue growth and
performance. Although ADMT believes the expectations
reflected in such forward-looking statements are based upon
reasonable assumptions, there can be no assurance that its
expectations will be realized. Forward-looking statements involve
risks and uncertainties that could cause actual results to differ
materially from expectations. Factors that could contribute
to such differences include those described from time to time in
ADMT’s SEC filings, news releases, and other communications. The
Company assumes no obligation to update the information contained
in this news release.
Andre DiMino
201-767-6040
andre@admtronics.com
Adm Tronics Unlimited (QB) (USOTC:ADMT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adm Tronics Unlimited (QB) (USOTC:ADMT)
Historical Stock Chart
From Sep 2023 to Sep 2024